Investors get a reality check in China as stockmarkets fall
The People’s Bank of China, started to remove liquidity from the financial system at the start of this year, driving stock prices down.

China's benchmark CSI 300 stockmarket index soared by 27% in 2020 thanks to the Covid-19-induced stimulus, but the rally peaked in February this year and the index has since tumbled by 13%. It has lost 4% since 1 January.
The main cause is tighter money, as Jacky Wong explains in The Wall Street Journal. The People’s Bank of China, the central bank, turned on the monetary taps last year in response to the virus. Yet with the recovery looking secure, it started to remove some of that liquidity from the financial system at the start of this year. “The spectre of bubbles past still haunt Chinese policy makers”: previous post-crisis stimulus efforts have saddled the financial system with a worrying debt burden. Regulators’ priority is curbing of speculation in property, but tighter credit brings “collateral damage” to stocks.
Big tech gets smaller
Chinese markets have also been affected by the ongoing global “rotation” away from highly-priced growth stocks (particularly technology companies) towards more cyclical sectors.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Shares in tech giants such as Alibaba, Baidu and JD.com were “hammered” last week after US regulators pressed forward with changes that could ultimately see the firms removed from US stock exchanges, reports Arjun Kharpal for CNBC. Many Chinese tech firms have dual listings in America in order to access a wider pool of investor capital.
Big Chinese tech firms are also under pressure in their home market from tighter regulation. Beijing appears to have concluded that the sector needs to be cut down to size to ensure social stability, says Eoin Treacy on Fuller Treacy Money. “Companies like Tencent and Alibaba” now face clear “limits” on how much further they can expand.
The market pullback hasn’t undermined an ongoing boom in initial public offerings (IPOs), notes Hudson Lockett in the Financial Times. The value of flotations in Hong Kong has hit $16.4bn so far this year, compared with just $1.8bn in the first three months of last year. Yet Chinese stocks are not the value play they once were. The CSI 300’s price/earnings ratio has risen from 12 to 19 over the past year.
Tighter money in China underlines a growing split between rich economies, where central banks plan to keep credit easy, and emerging markets, where central bankers are growing hawkish; Russia and Brazil both recently raised interest rates. China was “first in, first out” of the pandemic, Peiqian Liu of Natwest Markets told Sofia Horta e Costa and Richard Frost on Bloomberg.
Now, this “stockmarket rout” could provide another leading indicator for the rest of the world: “When central banks and governments start exiting pandemic-era stimulus” the results for investors are “not pretty”.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Alex is an investment writer who has been contributing to MoneyWeek since 2015. He has been the magazine’s markets editor since 2019.
Alex has a passion for demystifying the often arcane world of finance for a general readership. While financial media tends to focus compulsively on the latest trend, the best opportunities can lie forgotten elsewhere.
He is especially interested in European equities – where his fluent French helps him to cover the continent’s largest bourse – and emerging markets, where his experience living in Beijing, and conversational Chinese, prove useful.
Hailing from Leeds, he studied Philosophy, Politics and Economics at the University of Oxford. He also holds a Master of Public Health from the University of Manchester.
-
Reeves warned against property tax shake-up – 3 ways it could backfire on first-time buyers
Rachel Reeves reportedly has her eye on high-end property taxes in the upcoming Budget, but there are concerns a shake-up could unintentionally hamper those trying to get on the housing ladder
-
Average Brits want to retire five years before they can – who has the widest retirement gap?
Brits are expecting to work for longer than ever but there are big disparities in the number of extra working years predicted. A small tweak could help close the gap
-
Pierre-Édouard Stérin wants to make France great again
Conservative billionaire Pierre-Édouard Stérin is seeking to lead a political and spiritual renaissance across the Channel. The planning looks meticulous
-
Global investors have overlooked the top innovators in emerging markets
Opinion Carlos Hardenberg, portfolio manager, Mobius Investment Trust, highlights three emerging market stocks where he’d put his money
-
Pinewood Technologies: a drive for growth
Pinewood Technologies’ platform is one of the best in the business. Investors should buy in
-
'EV maker Faraday Future will crash'
Faraday Future Intelligent Electric is failing dismally to live up to its name, says Matthew Partridge
-
Investors should cheer the coming nuclear summer
The US and UK have agreed a groundbreaking deal on nuclear power, and the sector is seeing a surge in interest from around the world. Here's how you can profit
-
8 of the best houses for sale with follies
The best houses for sale with follies in the grounds – from a five-storey Victorian Gothic tower in Tonbridge, Kent, to a former mill in Oxfordshire with gardens that include a folly on an island in a lake
-
A tale of two Reits – why performance matters for valuation
AEW UK and Regional are two Reits that are valued very differently, despite a shared focus on properties outside London
-
Healthcare stocks look cheap, but tread carefully
Shares in healthcare companies could get a shot in the arm if uncertainty over policy in the US wanes, but are they worth the risk?